Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
14. Trade receivables
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| $000s | $000s | |
| Trade receivables | - | 972 |
The Group considers that the carrying amount of trade receivables approximates their fair value.
No interest is charged on outstanding receivables. There were no overdue trade receivables balances.
The Group has applied an expected credit loss model to the balance and determined thatno allowance is required for the periods ended December 31, 2025 and 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.